Long-Term Benefits of Osimertinib in Resected EGFR-Mutated NSCLC Highlighted in ADAURA Trial Update #South_Korea #Seoul #NSCLC #Osimertinib #ADAURA
@newsen.bsky.social
@newsen.bsky.socialLong-Term Benefits of Osimertinib in Resected EGFR-Mutated NSCLC Highlighted in ADAURA Trial Update #South_Korea #Seoul #NSCLC #Osimertinib #ADAURA
@cancertherapyadv.bsky.socialNew data from #WCLC26 found adding intercalating gefitinib to adjuvant platinum-based chemotherapy is associated with improved DFS for EGFR-altered #NSCLC! @iaslc.bsky.social 🫁
Read the full article: https://bit.ly/4xnnn9g
@newsen.bsky.socialZidesamtinib Shows Promising Results in ROS1-Positive NSCLC Patients #South_Korea #Seoul #NSCLC #zidesamtinib #ROS1-positive
@medchemexpress.bsky.social💊 #WCLC 2026 | Key Advances in #LungCancer Research
From B7-H3 ADCs to next-generation TKIs and combination strategies, WCLC 2026 highlights evolving approaches in #NSCLC and #SCLC:
🔗https://bit.ly/4xW10sT
@newsen.bsky.socialPAPILLON Study Reveals Promising Survival Rates for Advanced NSCLC with Amivantamab #Seoul #NSCLC #Amivantamab #PAPILLON #Republic_of_Korea
@yalecancer.bsky.socialDr. Henry Park presents a research poster at #WCLC in Seoul tonight on "Androgen Receptor Mutations in #NSCLC are Enriched in Females and Predict Better Immunotherapy Response."
cattendee.abstractsonline.com/meeting/21487/…
@iaslc.bsky.social
@newsen.bsky.socialLatest Findings on Sacituzumab Govitecan and Pembrolizumab in Treating NSCLC Fail to Show Significant Progress #South_Korea #Seoul #Sacituzumab #NSCLC #Pembrolizumab
@jamasurgery.comPerioperative toripalimab plus chemotherapy improved tumor and lymph node downstaging and event-free survival in resectable stage III #NSCLC without increasing perioperative complications. ja.ma/4iPepy0
@rcatanho.bsky.socialOsimertinib más quimioterapia aumenta la supervivencia libre de progresión en pacientes con cáncer de pulmón no microcítico avanzado con mutación EGFR que portan mutaciones TP53 #NSCLC #osimertinib #mutations jamanetwork.com/journals/jam...
@tamedoncol.bsky.socialOn #TAMO in 2025
💊 🫁 🧬
Real-world evidence on selpercatinib in RET-rearranged #NSCLC is limited. In this updated analysis of LIBRETTO-321, selpercatinib showed durable responses, prolonged survival, and a good safety profile in Chinese patients.
journals.sagepub.com/doi/full/10....
@pharmaphorum.bsky.social#Bayer has won #FDAapproval for #oralHER2inhibitor #Hyrnuo as a #firstlinetreatment for advanced HER2-mutant non-small cell lung cancer (#NSCLC), just a year after it was cleared as a second-line option.
@alliance-org.bsky.social📢 New Clinical Trial: Alliance A082302 is studying if immunotherapy after surgery prevents recurrence in early non-small cell lung cancer (#NSCLC). The trial aims to enroll 336 participants to move from passive observation to active prevention. More at https://bit.ly/43SStJU.
@oncoalert.bsky.socialFDA News🇺🇸 Sevabertinib Approved in Locally Advanced #NSCLC #LungCancer
On September 9, 2026, the FDA granted accelerated approval to sevabertinib (Hyrnuo) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 (ERBB2) TKD activating mutations
@lancetrespirmed.bsky.social📰 New Series from The Lancet and The Lancet Respiratory Medicine, launched 7th September at #ERS2026
Therapeutics in Lung Cancer www.thelancet.com/series-do/lu...
The Series includes three review papers on early stage #NSCLC, advanced NSCLC, and #SCLC
🔓All content is free to access for all
@sigtrans-sttt.bsky.social
@cancergrace.bsky.social📣 New Podcast! "Qualifying for Clinical Trials, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026" on @Spreaker #cancer #clinical #education #grace #lung #nsclc #qualifying #treatment #trial
@cancergrace.bsky.social@oncoalert.bsky.socialNEWS from Industry: HARMONI-2 Update in #NSCLC
Source businessWire
Akeso reports positive Phase III HARMONi-2 results showing that ivonescimab monotherapy significantly improved overall survival vs. pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer.
@pharmaphorum.bsky.social#Akeso and #Summit's PD-1xVEGF drug #ivonescimab has improved overall survival in another phase 3 trial, this time when used as a first-line treatment for PD-L1-positive non-small cell lung cancer (#NSCLC).